GLA antibody
Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
GLA antibody
category
Primary Antibodies
provider
FineTest
reference
FNab00328
tested applications
ELISA, IHC, IP, WB
Description
GLA, also named as Melibiase, Agalsidas and Alpha-galactosidase A, Belongs to the glycosyl hydrolase 27 family. It hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | galactosidase, alpha (GLA) |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Recommended Dilution | WB: 1:500-1:5000; IHC: 1:20-1:200; IP: 1:500-1:5000 |
| Clonality | polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Observed MW | 49 kDa |
| Purity | ≥95% as determined by SDS-PAGE |
| Purification | Immunogen affinity purified |
| Size 1 | 100µg |
| Form | liquid |
| Tested Applications | ELISA, IHC, IP, WB |
| Storage | PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.) |
| UniProt ID | P06280 |
| Gene ID | 2717 |
| Alias | Alpha-galactosidase A,Alpha-D-galactosidase A,Alpha-D-galactoside galactohydrolase,Galactosylgalactosylglucosylceramidase GLA,Melibiase,GLA |
| Background | Antibody anti-GLA |
| Status | RUO |
| Note | Mol. Weight 49 kDa |
Descripción
Related Products
Human GLA (Alpha-galactosidase A) ELISA Kit
Ver Producto
Porcine GLA (Alpha-galactosidase A) ELISA Kit
Ver Producto
GLA antibody
GLA, also named as Melibiase, Agalsidas and Alpha-galactosidase A, Belongs to the glycosyl hydrolase 27 family. It hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.
Ver Producto